Inhibikase Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -2.85M-14.79M-18.13M-20.09M-28.59M
Depreciation and Depletion 0.01M0.18M0.03M
Share-based Compensation 0.57M1.53M0.46M0.50M8.14M
Gains from Investment Securities 1.44M
Non-cash Items 2.00M0.30M31.10M
Cash from Operations -1.13M-14.30M-17.35M-18.09M-19.15M
Depreciation, Depletion & Amortization
Amortization of Deferred Charges 0.02M
Depreciation & Amortization (CF) 0.01M0.18M0.03M
Change in Working Capital
Change in Receivables 0.11M-0.07M-0.04M
Change in Account Payables -0.25M-0.63M0.06M-0.50M0.27M
Change in Accured Expenses -1.08M2.08M-0.32M-0.14M0.42M
Other Working Capital Changes 0.90M-2.33M-1.34M0.11M0.62M
Investing Activities
Capital Expenditures 0.24M0.01M
Cash from Investing Activities -16.01M11.66M-37.00M
Financing Activities
Other financing activities -0.14M
Cash from Financing Activities 15.06M41.09M-0.20M8.41M103.48M
Additional items
Change in Cash 13.94M26.80M-33.56M1.98M47.33M
Beginning Cash Balance 0.02M13.95M40.75M7.19M9.17M
Free Cash Flow -1.13M-14.30M-17.59M-18.10M-19.15M
Net Cash Flow 13.94M26.80M-33.56M1.98M47.33M